ONECUT2 is a driver of neuroendocrine prostate cancer

Neuroendocrine prostate cancer (NEPC) is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, resulting in resistance to AR-targeted therapy. Here they report ONECUT2 to drive NEPC tumorigenesis via regulation of hypoxia signaling and tumor hypoxia, a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Haiyang Guo, Xinpei Ci, Musaddeque Ahmed, Junjie Tony Hua, Fraser Soares, Dong Lin, Loredana Puca, Aram Vosoughi, Hui Xue, Estelle Li, Peiran Su, Sujun Chen, Tran Nguyen, Yi Liang, Yuzhe Zhang, Xin Xu, Jing Xu, Anjali V. Sheahan, Wail Ba-Alawi, Si Zhang, Osman Mahamud, Ravi N. Vellanki, Martin Gleave, Robert G. Bristow, Benjamin Haibe-Kains, John T. Poirier, Charles M. Rudin, Ming-Sound Tsao, Bradly G. Wouters, Ladan Fazli, Felix Y. Feng, Leigh Ellis, Theo van der Kwast, Alejandro Berlin, Marianne Koritzinsky, Paul C. Boutros, Amina Zoubeidi, Himisha Beltran, Yuzhuo Wang, Housheng Hansen He
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/15eb3a591377407ab3aae62e9aca95cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

ONECUT2 is a driver of neuroendocrine prostate cancer

Ejemplares similares